Vernalis logo

VER - Vernalis Share Price

6.17p 0.0  0.0%

Last Trade - 09/10/18

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £11.5m
Position in Universe th / 1805
Bullish
Bearish
Unlock VER Revenue
Momentum
Relative Strength (%)
1m +0.043%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2013 2014 2015 2016 2017 2018 2019E 2020E CAGR / Avg
14.6 14.1 19.9 12.0 18.7 11.5 22.6 45.9 -4.7%
+43.8
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2018, Vernalis plcrevenues decreased 38% to £11.5M. Net loss beforeextraordinary items totaled £5.3M vs. income of £5.9M.Revenues reflect Research and development segment decreaseof 40% to £8.7M, Commercial segment decrease of 34% to£2.8M, Europe segment decrease of 25% to £10.7M, NorthAmerica segment decrease from £2.4M to £0K, Rest of theWorld segment decrease of 58% to £822K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VER Revenue Unlock VER Revenue

Net Income

VER Net Income Unlock VER Revenue

Normalised EPS

VER Normalised EPS Unlock VER Revenue

PE Ratio Range

VER PE Ratio Range Unlock VER Revenue

Dividend Yield Range

VER Dividend Yield Range Unlock VER Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VER EPS Forecasts Unlock VER Revenue
Profile Summary

Vernalis Ltd, formerly Vernalis plc, is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. It also has over four prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.

Directors
Last Annual June 30th, 2018
Last Interim June 30th, 2018
Incorporated October 13, 1988
Public Since July 1, 1992
No. of Shareholders: n/a
No. of Employees: 192
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange London Stock Exchange
Shares in Issue 526,986,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VER Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VER
Upcoming Events for VER
Frequently Asked Questions for Vernalis
What is the Vernalis share price?

As of 09/10/18, shares in Vernalis are trading at 6.17p, giving the company a market capitalisation of £n/a. This share price information is delayed by 15 minutes.

How has the Vernalis share price performed this year?

Shares in Vernalis are currently trading at 6.17p and the price has moved by -52.54% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vernalis price has moved by -52.48% over the past year.

What are the analyst and broker recommendations for Vernalis?

Of the analysts with advisory recommendations for Vernalis, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Vernalis is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Vernalis next release its financial results?

Vernalis is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2019-06-30
What is the Vernalis dividend yield?

Vernalis does not currently pay a dividend.

Does Vernalis pay a dividend?

Vernalis does not currently pay a dividend.

When does Vernalis next pay dividends?

Vernalis does not currently pay a dividend.

How do I buy Vernalis shares?

To buy shares in Vernalis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vernalis?

Shares in Vernalis are currently trading at 6.17p, giving the company a market capitalisation of £n/a.

Where are Vernalis shares listed? Where are Vernalis shares listed?

Here are the trading details for Vernalis:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: VER
What kind of share is Vernalis?

We were not able to load our ranking data for Vernalis

Is there a Vernalis share price forecast 2021?

We were not able to load any forecast data for Vernalis.

How can I tell whether the Vernalis share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vernalis. Over the past six months, the relative strength of its shares against the market has been 46.8%. At the current price of 6.17p, shares in Vernalis are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vernalis PE Ratio?

We were not able to find PE ratio data for Vernalis.

Who are the key directors of Vernalis?

Vernalis's management team is headed by:

Peter Fellner - NEC
Carol Ferguson - NID
Ian Garland - CEO
David Mackney - CFO
Kevin Kissane - SEC
Nigel Sheail - NID
Lisa Schoenberg - NED
Who are the major shareholders of Vernalis?

Here are the top five shareholders of Vernalis based on the size of their shareholding:

Similar to VER
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.